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mal control group and HCV-related chronic hepatitis regarding
the HGFA H-score and TGF-β1 H-score.
Conclusions: Parallel expression of HGFA and TGF-β1 with the
grade of activity and stage of ﬁbrosis in HCV-related chronic hep-
atitis could make HGFA as an activity and regenerative marker.
PP-138 Screening and cloning of gene of hepatocyte
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Lian-feng Zhang1, Jun Cheng*,2, Li-dong Chen3, Ji-chang Li 1,
Wei Liu. 1The First Afﬁliated Hospital of Zhengzhou University;
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Objective: We screen proteins of hepatocyte protein interacting
with hepatitis C virus NS5ATP4A protein to clarify the signal
transduction pathway of HCV.
Methods: “Bait” plasmids of hepatitis C virus NS5ATP4A were
constructed. After verifying that hepatitis C virus NS5ATP4A pro-
tein could be steadily expressed in AH109 yeast strain, yeast-two
hybrid assay was performed by mating AH109 with Y187 that
pre-transformed with liver cDNA library plasmids pACT2, and the
diploidy yeast cells were plated on quadruple dropout (QDO)
medium and assayed for X-α-gal activity. Nineteen yeast colonies
that could grow on QDO and hadα-gal activity were obtained,
then the library plasmids were extracted and sequenced.
Results: 7 genes were screened out and one of them was un-
known gene. These genes were associated RNA synthesis, protein
translation, cell cycle and tumor immune.
Conclusion: NS5ATP4 binding proteins were successfully
screened,which offer new clues to the signal transduction path-
way of NS5ATP4A and the pathogenic mechanism of HCV.
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Aim: The evaluation of ﬁbrosis through Ishak and Metavir scoring
systems and it’s progression rate.
Methods: We studied 242 naïve patients with chronic hepatitis
C, admitted between 2003 and 2006, who performed liver biopsy
for diagnosis, being evaluated according two scoring systems.
The evaluation of the ﬁbrosis progression rate was performed
only in 55 patients with a previous history of transfusions, using
the ratio between the ﬁbrosis stage and the estimated infection
duration (years).
Results: The mild and moderate ﬁbrosis lesions predominated,
with a concordance between the scoring systems.
The mean ﬁbrosis index was signiﬁcantly larger in patients with
moderate/severe necroinﬂamatory lesions, irrespective of the
normal or increased AST or ALT levels.
The mean ﬁbrosis progression rate of 0.23±0.34 units/year ac-
cording to the Metavir system, and 0.32±0.51 units/year - Ishak
system.
The age at the time of infection and it’s estimated duration
correlate with the Metavir ﬁbrosis progression rate (p =0.000,
respectively p =0.001). The patients who have been infected
before the age of 40 and those with a duration of infection of less
than 20 years have a signiﬁcantly lower mean ﬁbrosis progression
rate.
Conclusions: 1. The mild and moderate ﬁbrosis predominated,
with equivalent results between the two scoring systems.
2. The severity of ﬁbrosis correlated with the age and the
increased AST or ALT levels.
3. The mean ﬁbrosis progression rate was 0.23±0.34 units/year in
the Metavir system, respectively 0.31±0.51 units/year in Ishak,
being correlated with the age at the moment of infection and it’s
estimated duration of evolution.
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Dana Damian*, Mircea Grigorescu, Mircea Dan Grigorescu,
Teodor Zaharie. Third Medical Clinic, Cluj Napoca, Romania
Aim: evaluating the presence and localisation of the HCV anti-
gens (NS3, NS5, NS5A) in patients with chronic hepatitis C and
undetectable versus detectable serum HCV-RNA.
Methods: 93 patients with chronic hepatitis C were included in
the study, 55 with detectable viremia. Using immunohistochem-
ical techniques involving monoclonal and policlonal antibodies,
we analysed the presence, localisation and semiquantitative
grading of coloured cells.
Results: All untreated patients with detectable viremia pre-
sented hepatocyte expression of viral proteins, especially in the
hepatocyte cytoplasm and less in the nucleus. The untreated sub-
jects with undetectable viremia had similar detection rate as the
untreated patients with detectable viremia, 92.3% respectively
92.4% and 84.61% for NS3, NS5, NS5A.
In treated patients with undetectable viremia, the proportion
of positive results were comparable for NS3 (92%) but lower
for NS5 and NS5A (80% and 60%). The positive immunohisto-
chemical reaction was observed in fewer hepatocytes (< 30%),
with focal lobular distribution and mild/moderate intensity in
treated subjects with undetectable viremia, respectively moder-
ate/important in the rest of patients.
The patients with undetectable viremia were found to have cor-
relationships between the presence of NS3 and NS5 antigens and
the ﬁbrosis level. The presence of steatosis correlated with NS3
and NS5 only in untreated patients with undetectable viremia.
The portal space involvement was observed especially at
macrophages.
Conclusions: Identifying the presence of viral antigens in the
liver tissue in patients with undetectable viremia, who have
either received antiviral therapy or not, can bring into discussion
the occult HCV infection.
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Objectives: Chronic hepatitis C virus (CHC) infection is treated
with interferon/ribavirin, but only a subset of patients re-
spond. We previously reported that treatment nonresponders
have marked pre-treatment upregulation of a subset of inter-
feron stimulated genes (ISGs) in their livers, including ISG15
(Chen, et al. Gastroenterology 2005). Here, we study the source
of the ISG expression signature and uncover the cellular basis of
the phenotype through ISG15 and MxA protein expression.
Methods: ISG15 and MxA immunohistochemistry was performed
on a subset of 31 liver biopsies and the expression pattern was
correlated with response status.
Results: Using a simple histology scale scored from 0 to 3
(0: no staining in any cell, 3: staining in every cell), we
found signiﬁcantly more hepatocyte ISG15 expression in treat-
ment non-responders versus responders (2.4±0.6 vs 1.1±0.6,
p<0.0001), but less macrophage ISG15 staining (0.2±0.4 vs
0.8±0.6, p<0.005). MxA protein expression had a similar cell-
speciﬁc pattern of expression. Treatment response was linked
to cell-speciﬁc activation patterns: ISG15 and MxA protein up-
regulation was more pronounced in hepatocytes in treatment
nonresponders, but in Kuppfer cells in responders.
Conclusions: Our previously deﬁned differential gene expression
pattern in the livers of HCV responders and nonresponders is
driven by activation of different cell types: hepatocytes in treat-
ment nonresponders, and macrophages in treatment responders.
